Cellectis (CLLS) Competitors $2.76 -0.06 (-2.13%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLLS vs. TSHA, VIR, TERN, RLAY, SIGA, ORGO, MAZE, KROS, TRML, and ORKAShould you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Taysha Gene Therapies (TSHA), Vir Biotechnology (VIR), Terns Pharmaceuticals (TERN), Relay Therapeutics (RLAY), Siga Technologies (SIGA), Organogenesis (ORGO), Maze Therapeutics (MAZE), Keros Therapeutics (KROS), Tourmaline Bio (TRML), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry. Cellectis vs. Its Competitors Taysha Gene Therapies Vir Biotechnology Terns Pharmaceuticals Relay Therapeutics Siga Technologies Organogenesis Maze Therapeutics Keros Therapeutics Tourmaline Bio Oruka Therapeutics Taysha Gene Therapies (NASDAQ:TSHA) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends. Do analysts prefer TSHA or CLLS? Taysha Gene Therapies currently has a consensus target price of $8.29, suggesting a potential upside of 188.70%. Cellectis has a consensus target price of $4.00, suggesting a potential upside of 44.40%. Given Taysha Gene Therapies' higher possible upside, equities research analysts clearly believe Taysha Gene Therapies is more favorable than Cellectis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Cellectis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of TSHA or CLLS? 77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, TSHA or CLLS? Taysha Gene Therapies has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500. Is TSHA or CLLS more profitable? Cellectis has a net margin of -100.69% compared to Taysha Gene Therapies' net margin of -1,144.97%. Cellectis' return on equity of -68.05% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-1,144.97% -78.44% -44.82% Cellectis -100.69%-68.05%-21.53% Does the media refer more to TSHA or CLLS? In the previous week, Taysha Gene Therapies had 15 more articles in the media than Cellectis. MarketBeat recorded 15 mentions for Taysha Gene Therapies and 0 mentions for Cellectis. Cellectis' average media sentiment score of 1.45 beat Taysha Gene Therapies' score of 0.28 indicating that Cellectis is being referred to more favorably in the news media. Company Overall Sentiment Taysha Gene Therapies Neutral Cellectis Positive Which has preferable valuation and earnings, TSHA or CLLS? Cellectis has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$8.33M73.96-$89.30M-$0.34-8.44Cellectis$49.22M3.13-$36.76M-$0.82-3.38 SummaryCellectis beats Taysha Gene Therapies on 9 of the 15 factors compared between the two stocks. Get Cellectis News Delivered to You Automatically Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLLS vs. The Competition Export to ExcelMetricCellectisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$153.96M$3.11B$5.73B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-3.3820.4330.4625.16Price / Sales3.13238.54392.5887.62Price / CashN/A42.3737.0358.50Price / Book1.587.918.956.21Net Income-$36.76M-$54.72M$3.26B$265.38M7 Day Performance-3.15%1.66%1.06%-1.13%1 Month Performance51.37%5.89%4.31%-0.71%1 Year Performance17.62%8.72%28.40%18.86% Cellectis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLLSCellectis3.3286 of 5 stars$2.77-1.8%$4.00+44.4%+22.6%$153.96M$49.22M-3.38290Positive NewsShort Interest ↓Gap DownTSHATaysha Gene Therapies3.384 of 5 stars$2.93-0.3%$8.29+182.8%+25.3%$631.10M$8.33M0.00180Analyst RevisionVIRVir Biotechnology3.3644 of 5 stars$4.48-0.9%$30.25+575.2%-50.5%$627.90M$74.21M0.00580Positive NewsTERNTerns Pharmaceuticals3.4933 of 5 stars$6.76-4.1%$15.63+131.1%-16.1%$616.95MN/A0.0040News CoverageRLAYRelay Therapeutics2.0166 of 5 stars$3.47-2.0%$17.25+397.1%-53.1%$610.34M$10.01M0.00330SIGASiga Technologies2.1044 of 5 stars$8.92+4.9%N/A-0.7%$608.65M$138.72M7.5240News CoverageOptions VolumeORGOOrganogenesis4.1846 of 5 stars$4.58-3.2%$7.50+63.8%+70.3%$600.04M$482.04M0.00950Positive NewsMAZEMaze TherapeuticsN/A$13.35-1.1%$25.60+91.8%N/A$591.99M$167.50M0.00121Analyst RevisionKROSKeros Therapeutics2.9458 of 5 stars$14.52+0.3%$30.00+106.6%-69.9%$588.11M$3.55M46.71100News CoverageTRMLTourmaline Bio2.393 of 5 stars$22.17-1.8%$50.14+126.2%+56.6%$579.72MN/A-6.4644Analyst RevisionORKAOruka Therapeutics2.3219 of 5 stars$15.25-0.8%$40.38+164.8%N/A$575.62MN/A0.00N/ANews CoverageAnalyst ForecastAnalyst RevisionGap Up Related Companies and Tools Related Companies TSHA Alternatives VIR Alternatives TERN Alternatives RLAY Alternatives SIGA Alternatives ORGO Alternatives MAZE Alternatives KROS Alternatives TRML Alternatives ORKA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLLS) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access